We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Malvern Panalytical and Concept Life Sciences Announce Integration

Malvern Panalytical and Concept Life Sciences Announce Integration content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Malvern Panalytical (Malvern, UK and Almelo, The Netherlands), manufacturer of analytical systems, and Concept Life Sciences (Cheshire, UK), a contract research organization, have announced a full business integration. The integration will expand the existing analytical instrument and service relationship (Amplify Analytics) to include the Chemistry and Biology services of CLS. Both entities are operating businesses within the Spectris plc Group.

Mark Fleiner, President, Malvern Panalytical, expressed excitement about the opportunities presented by the integration: “Everyone at Malvern Panalytical is deeply committed to supporting our customers in delivering the pharmaceutical and agrochemical products needed to improve our health and quality of life. During this pandemic, we’ve already seen how, together with our customers, we can play a small but important role in enabling the development of vital medicines and treatments which can make a big contribution to the health of the world. We are all delighted to significantly build on our capability to achieve this with the passion, expertise and commitment of the combined Malvern Panalytical and Concept Life Sciences teams.”

The integration builds on the companies’ 2020 launch of Amplify Analytics - a range of flexible services designed to help pharmaceutical organizations identify new drug candidates and de-risk the process of developing robust formulations. The success of the collaboration has been demonstrated in the significant value delivered to clients, providing the insight needed to bring pharmaceutical products to market quickly and efficiently.

Although the union of the two businesses will bring new approaches to client support, the strong commitment of CLS to its existing clients remains unchanged.  Mark Carnegie-Brown, President of CLS, confirmed: “We have made sure that there is a seamless transition to the Malvern Panalytical platform for all our clients, free from changes to key contacts and existing service and confidentiality agreements.  Our clients should not notice any changes to how we interact with them, but they will see expanded access to all capabilities and expertise across Concept Life Sciences and Malvern Panalytical. Our excited and enthused combined teams are eager to explore the unique opportunities delivered by our integration.”